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Accept or Refuse? A Pilot Study of Patients’ Perspective 
on Participating as Imaginary Research 
Subjects in Schizophrenia 
 
 
 
ObjectiveaaThe goal of the present study was to evaluate demographic and clinical factors 
that affect the intention to participate in commonly-conducted research in patients with schi-
zophrenia. 
MethodsaaThirty-four outpatients with a diagnosis of schizophrenia were enrolled in this 
study. They were asked whether they would have any intention to participate in four imag-
inary studies: a simple questionnaire, a genetic study, a study of complex tasks and a risky 
study. We analyzed the differences in general psychopathology, insight and demographic 
characteristics of the participants according to their responses (acceptance or refusal) to 
the four proposed studies. 
ResultsaaYounger and better-educated patients tended to decline participation in a risky 
study. Patients with a longer duration of regular psychiatric follow-ups tended to willingly 
participate in the simple questionnaire. There were no overall statistical differences in ge-
neral psychopathology and insight between patients who agreed or declined to participate 
in studies. 
ConclusionaaAge and education level may be factors that influence decisions to partici-
pate in schizophrenia studies. Further research is needed to confirm and expand on the cur-
rent findings. 
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Introduction 
 
Voluntarism is the most basic ethical issue in medical research and human rights.
1
Debate of the ethical issues surrounding medical research began mainly after the Na-
zis performed non-consensual experiments on individuals under arrest. These debates 
resulted in the declaration of ten principles to govern studies using human subjects. 
Named after the important trial of Nazi war crimes, the Nuremberg Code was esta-
blished as the most famous code of ethics relating to medical research.
2 Thereafter, 
voluntary participation became an essential part of conducting research with human 
subjects. Recent developments in psychiatric research have introduced methodology
varying in complexity, from simple questionnaires to neuropsychological study, and
from genetic studies to new drug development trials. Consideration given to subject 
recruitment has become more complex and detailed.
3-5 Informed consent can be de-
fined as the process by which individuals make free decisions with adequate know-
ledge about the consequences of participation. Informed consent has been particularly 
important in psychiatric research, owing to the debate over the ability of patients to
provide it. Specific conditions of the patients make this a more relevant topic in psy-
chiatry compared with other medical fields.
6-8 Disabilities due to psychiatric symp- 
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toms are likely to interfere with appropriate methods of 
informed consent.
9 The minimal components that fulfill 
an appropriate informed consent process are understand-
ing, intention and voluntariness.
10 Some have also added 
communication skills to the components described above.
11 
Understanding implies the ability to comprehend the pur-
pose, procedure, risk and benefit of a study. Intention is the 
willingness, which reflects individual values, to participate 
in a study after consideration of the suggestion by a resear-
cher or a treating psychiatrist. Voluntariness is related to 
intention, implying that the person’s decision is free of 
outer or inner enforcement.
12 Unfortunately, some psychia-
tric patients are unable to fulfill the above conditions.
13-23 
Data about factors related to influence on, or the cap-
acity to provide, informed consent, have accumulated. 
However, the influence of patients’ demographic or cli-
nical characteristics on their perspective on study parti-
cipation has not been evaluated fully. For example, if the 
patients’ perspectives on the study resulted in the exclu-
sion of a specific population, selection bias could limit 
the generalizability of the study.
24-26 This problem is par-
ticularly difficult because it cannot be corrected or mo-
dified after study completion.
27,28 The difference in the 
psychopathology and in detailed clinical variables could 
not be obtained from individuals who decline to partici-
pate in the study, as they would not provide a detailed 
clinical history. Questionnaires about imaginary studies 
can be an alternative to studying this topic, and can give 
us a more comprehensive view of selection bias and the 
factors related to intentions of specific study subjects. Mo-
reover, the information could help to determine which 
studies may be acceptable while others are refused. How-
ever, little data is available regarding the factors related 
to patients’ participation in specific studies.   
The ability to evaluate the intention of schizophrenic 
patients can reveal useful information about the selec-
tion bias on patients’ perspective on being a part of three 
common types of procedures for which informed consent 
is required. The purpose of this exploratory study was to 
examine how psychopathology and other patient vari-
ables could be related to the likelihood that they would 
be inclined to participate in four imaginary studies de-
signed to reflect actual clinical practices.   
 
Methods 
 
The study population consisted of 34 subjects who 
gave informed consent to participate in this study. The 
subjects were recruited from the Seoul National Hospi-
tal, Seoul, Korea. All participants were outpatients diag-
nosed with DSM-IV-TR
29 Schizophrenia. Diagnosis was 
confirmed by the agreement of two psychiatrists. Clini-
cal and demographic characteristics such as sex, age, ed-
ucation level, employment status, previous history of study 
participation, and duration of continuous contact with the 
primary care psychiatrist were collected. Based on patients’ 
answers, their history of previous study participation was 
divided into three groups: simple questionnaire study, 
open-label drug study and double-blind placebo study. 
The Positive and Negative Syndrome Scale for Schizo-
phrenia (PANSS)30 was used to evaluate their psychopa-
thology and the General psychopathology item 12 (G12) 
of PANSS (lack of judgment and insight)30 was used to 
assess the level of insight of the patients. 
 
Study tools: informed consent to imaginary 
studies 
We developed questionnaires to evaluate the intention 
to participate in four imaginary studies. We named these 
questionnaires the simple questionnaire study (SS), the 
genetic study (GS), the complex study (CS) and the risky 
study (RS), according to the main feature of each study. 
The procedure of the current study was very simple. We 
presented the patients with informed consent forms for 
the four imaginary studies, and asked them whether they 
would participate in these studies if they were real. In 
addition to the basic explanation of each study, the fol-
lowing emphases were used. SS was a simple pen and 
paper questionnaire study, GS required blood sampling, 
CS required a complex neuropsychological battery and 
some time to complete and RS required them to switch 
their current antipsychotic medication and undergo a 
double-blind procedure, if needed. Table 1 summarizes 
the main point of each study explanation. Other proce-
dures followed a typical study design in each study area. 
Possible adverse events and gains were also explained. 
We minimized selection bias due to misunderstanding of 
each study purpose by using a figure and flow chart me-
thod, since the understanding or misunderstanding of a 
specific study is of interest to the current study.   
 
Statistical analysis  
Spearman’s correlation coefficient was used to evalu-
ate the correlation between the history of previous study 
TABLE 1. Key characteristics of the four current study types
 SS  GS  CS  RS 
1. Simple  1. Invasive  1. Takes a long time  1. Risk-taking 
Key features 
2. Takes a short time  2. Needs family information  2. Needing efforts  2. Taking new drug 
SS: simple study, GS: genetic study, CS: complex study, RS: risky study    
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participation and the four imaginary study participation 
intentions. Patients’ clinical variables and demographic 
characteristics were compared using either independent 
t-test or Fisher’s exact test between study participants and 
study refusal subjects in 4 imaginary studies. All statis-
tical analysis was performed using the Statistical Package 
for the Social Sciences (SPSS) 15.0 Windows version, 
and the significance level was set at p<0.05.   
 
Results 
 
Clinical variable and demographic characteristics  
Study subjects comprised slightly more men than wo-
men (n=18, 52.90%) and the mean age was 37.26 years. 
The simple questionnaire study was the most common 
procedure previously experienced by the subjects (n=24, 
70.60%). The mean duration of illness was 11.91 years. 
The mean duration of continuous contact with a primary 
care psychiatrist was 20.71 months. The mean PANSS 
score was 68.09 and the mean G12 score of PANSS 
(higher scores mean greater lack of insight)30 was 3.50. 
The clinical variables and demographic characteristics 
are illustrated in Table 2.   
 
Patients’ willingness to participate overall and in 
each study  
We obtained a total of 54 informed consents, out of 
136 possible study participations (34 people×4 question-
naires). Thus, the study population agreed to participate 
at the rate of 39.71%. As shown in Figure 1, subjects 
were often willing to participate in SS, they were less li-
kely to participate in GS. The intentions of participations 
between the GS, CS, and RS were significantly correlat-
ed with each others, but not the SS (Table 3). 
TABLE 3. Spearman’s Correlation Coefficient between patients’ 
willingness to participate in the four current study types (N=34) 
  SS GS CS RS 
SS -  0.306  0.218* 0.072* 
GS -  -  0.533*  0.459* 
CS -  -  -  0.615* 
*p<0.05. SS: simple study, GS: genetic study, CS: complex study, 
RS: risky study 
 
TABLE 2. Baseline characteristics of participants (N=34)
 N  %  Mean  SD 
Male 18  52.90     
Age     37.26  08.98 
Education (yrs)     12.79  02.14 
Employed 12  35.40     
DOI (yrs)     11.91  08.36 
DOF (months)    20.71  14.57 
Hx of SQS  24  70.60     
Hx of ODS  14  41.20     
Hx of RDP  04 11.80     
PANSS     68.09  14.06 
PANSS G12      03.50  01.33 
SD: Standard deviation, DOI: duration of schizophrenia illness,
DOF: duration of follow-up with the primary care psychiatrist in
outpatient department, Hx: history, SQS: simple questionanaire
study, ODS: open-label drug study, RDP: randomized double
blind placebo controlled sutyd, PANSS: Positive and Negative
Syndrome Scale for Schizophrenia, G12: General psychopatho-
logy item 12 
 
TABLE 4. Relationship between previous history of study participation and the willingness to participate in the current four study types. Data 
were calculated by Fisher’s exact test (N=34) 
SS GS  CS  RS 
 
Yes  No  p value  Yes  No  p value  Yes  No  p value  Yes  No  p value 
Yes  21  3 0.157 10  14 0.718 11  13 0.708 07 17  0.271  Hx of SS 
No  06 4    05  05  06  04  05  05  
Yes 12  2  0.672  05  09 0.495 04 10  0.080  03 11  0.275  Hx of ODS 
No  15  5  10  10  13  07  09 11   
Yes  03 1  1.000  02  02 1.000 02  02 1.000 02  02 0.602  Hx of RDP 
No  24  6  13  17  15  15  10  20   
SS: simple study, GS: genetic study, CS: complex study, RS: risky study, Hx: history, SS: simple questionnaire study, ODS: open-label drug 
study, RDP: randomized double-blind placebo-controlled study   
(%)
100
80
60
40
20
0
S S                GS               C S                R S  
N o        Ye s 
FIGURE 1. Percentage of patients agreeing to participate in each
type of study. SS: simple study, GS: genetic study, CS: complex
study, RS: risky study, No: unwilling to participate in the study,
Yes: willing to participate in the study.  
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The relationship between previous history of 
study participation and current study 
participation  
As shown in Table 4, the subjects’ previous history of 
study participation was not correlated with their partici-
pation in the current imaginary studies.   
 
The relationships between demographic or cli-
nical variables and study participation intentions 
In RS, there was significant difference in the age and 
years of education between study participants and non-
participants. In SS, study participants had a significantly 
longer duration of continuous contact with a primary care 
psychiatrist compared with study non-participants. There 
were no differences in PANSS and G12 of PANSS be-
tween study participants and study non-participants in 
all four studies. These results are summarized in Table 5. 
 
Discussion 
 
We investigated the intention of schizophrenia patients 
to participate in four imaginary studies developed by us. 
We explored the factors related to their intention to par-
ticipate in each study.   
In this study, about 40% of all study subject patients 
chose to participate in at least one imaginary study. A 
relatively low proportion of patients were willing to par-
ticipate in GS or RS. This result showed that patients 
were considering possible risks related to a specific study. 
Blood sampling and placebo clinical trials pose a poten-
tial risk for patients who participate. The current study 
population consisted of relatively clinically-stable out-
patients who had little desire to expose themselves to a 
specific risk. As a result, GS or RS studies likely attract 
only a specific subset of the entire schizophrenic popu-
lation. However, this possible selection bias occurs only 
in the case of SS and RS. Younger and more highly-ed-
ucated people tended to decline participation in the RS 
study. This may reflect the greater potential for risk ev-
aluation, although the current study did not explain the 
phenomenon fully. For SS, a longer duration of contact 
with a primary care psychiatrist was correlated with will-
ingness to participate in a SS. Rapport or compliance can 
affect the intention of research participation in SS. Yet, 
only seven patients chose non-participation; such a small 
sample size means the result cannot be explained fully 
in the current context and the conclusion must be deferred. 
Another interesting result of this study was the correla-
tion between the patients’ intention to participate in each 
study. These correlations were found in all imaginary st-
udies except GS. As described above, the lack of will-
ingness to participate in GS could be related to another 
p
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possible factor. However, participation in one study can 
be correlated with participation in another study. As one 
patient’s perspective revealed, the three (GS, CS, RS) st-
udies were viewed in a similar way and a similar me-
chanism was used to decide willingness of study partici-
pation. Willingness of study participation was very simi-
lar across different study subjects in people with schizoph-
renia; other clinical variables and demographic characte-
ristics were not different between those who chose or de-
clined to participate. Taken together, the current findings 
indicate that a specific population of schizophrenia pa-
tients is likely to participate or decline to participate in re-
search, regardless of the study type. However, the choice 
to participate in a specific study appears to relate not to 
the severity of the patients’ psychopathology, but rather to 
demographic factors (i.e., age and level of education).  
Our exploratory study had several limitations. The st-
udy sample was small and exclusive to schizophrenia out-
patients, which limits the ability to generalize the results 
of this study to the general schizophrenia population. 
The lack of significant results for some variables, could 
have been due to low statistical power. In contrast, mul-
tiple analyses could have result in type I errors since we 
analyzed the difference of some demographic data with-
out accurate study hypothesis or interest of variable. In 
this study, we included only some clinical and demogra-
phic variables; neuropsychological tests or comprehen-
sive clinical variables would strengthen the predictive 
power of our approach, and could give us greater insight 
into other factors related to the intention of study parti-
cipation. Another limitation is the inability to compare 
current study results to previous results, as few results 
from previous literature are relevant to the approach 
taken here. It is possible that there would be some differ-
ence in subjects’ responses when faced with real as op-
posed to imaginary choices. In addition, the validity of 
the research questionnaire was not assessed, since this 
was outside of the scope of this pilot study. Despite these 
limitations, the results of this pilot study, in conjunction 
with other studies on the subject, provide a point of re-
ference for the field of schizophrenia research.   
In conclusion, some demographic or clinical factors 
could be related to a specific study type, and patients’ 
participation in each of the different studies is correlated. 
Further studies are needed to clarify this issue and con-
tribute to an improved framework for interpreting rese-
arch results in schizophrenia research.   
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